Researchers have studied glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including liraglutide, semaglutide, and tirzepatide, which improve glycemic control, promote weight loss, reduce inflammation, and enhance endothelial function in patients with type 2 diabetes [11,12]. Here, GLP1R is linked to type 2 diabetes mellitus.